Literature DB >> 30926357

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.

Roxana Reyes1, Clara Mayo-de-Las-Casas2, Cristina Teixidó3, Carlos Cabrera1, Elba Marín4, Ivan Vollmer5, Pedro Jares6, Mónica Garzón2, Miguel Ángel Molina-Vila2, Noemí Reguart7.   

Abstract

Entities:  

Keywords:  BRAF kinase activity; BRAF mutation; BRAF/MEK blockade; NGS; NSCLC

Mesh：

Substances：

Year:  2019        PMID： 30926357     DOI： 10.1016/j.cllc.2019.02.022

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.

Authors:  Alla Turshudzhyan; James Vredenburgh
Journal:  Curr Oncol       Date:  2020-12-25       Impact factor: 3.677

Review 2.  [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].

Authors:  Hongxia Zhang; Jinsheng Gao; Wei Guo; Bo Yu; Haitao Yang; Yutao Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-02-20

Review 3.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.